Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury

Diabetes

Volumn 51, Issue 5, 2002, Pages 1507-1514

  Khandoudi, Nassirah ^a   Delerive, Philippe ^b,c   Berrebi Bertrand, Isabelle ^a   Buckingham, Robin E ^a   Staels, Bart ^b,c   Bril, Antoine ^a  

^a GLAXOSMITHKLINE   (United States)

^b INSERM   (France)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; STREPTOZOCIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPSIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA FLOW; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CONVALESCENCE; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FUNCTIONAL ASSESSMENT; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT PLANNING; WESTERN BLOTTING;

EID: 0036319490     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.5.1507     Document Type: Article

References (32)

1. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart: p38/RK mitogen-activated protein kinases are activated by ischemia/reperfusion
2. Stimulation of c-jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the perfused rat heart
3. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats
4. c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases
5. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney
6. Differential expression of peroxisome proliferator-activated receptors (PPAR-s): Tissue distribution of PPAR-α, -β, and -γ in the adult rat
7. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR-) isoforms PPAR-γ2 versus PPAR-γ 1 and activation with retinoid X receptor agonists and antagonists
8. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
9. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR-γ)
10. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes: Association with increased insulin binding and cell-surface GLUT 4 as measured by photoaffinity labeling
11. The peroxisome proliferator activated -γ is a negative regulator of macrophage activation
12. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
13. The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes
14. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes
15. Protective effect of the sodium/hydrogen exchange inhibitors during global low-flow ischemia
16. Effect of pressure development on oxygen consumption by isolated rat heart
17. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ
18. + exchange during ischaemia and reperfusion of normal and diabetic rat hearts
19. Effects of an intravenous infusion of a glucose-potassium-insulin solution on the electrocardiographic signs of myocardial infarction
20. PPAR-γ activators down-regulate the expression of PPAR-γ in 3T3-L1 adipocytes
21. The stress-activated protein kinase subfamily of c-Jun kinases
22. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
23. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway
24. Roles of PPAR-s in health and disease
25. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats
26. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes
27. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs
28. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat
29. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells
30. 2 and troglitazone: Evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression
31. Endogenous PPAR-γ mediates anti-inflammatory activity in murine ischemia-reperfusion injury
32. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activator receptor-γ, agonist rosiglitazone